[324 Pages Report] The global myelodysplastic syndrome treatment market is poised to register a 5.9% CAGR, capturing a revenue share of US$ 2,990.8 million in 2022, to reach US$ 5,614.1 million by 2032.
| Report Attribute | Details |
|---|---|
| Myelodysplastic Syndrome Treatment Market Value (2022) | US$ 2,990.8 Million |
| Myelodysplastic Syndrome Treatment Market Anticipated Forecast Value (2032) | US$ 5,614.1 Million |
| Myelodysplastic Syndrome Treatment Market Projected Growth Rate (2022-2032) | 5.9% |
The rising adoption of myelodysplastic syndrome treatment can be attributed to new drugs and drug combinations that may work better and have less severe side effects that are the subject of studies.
Currently, the myelodysplastic syndrome treatment market trends are shaped by some of the most effective medications for treating MDS, classified as hypomethylating agents, such as azacitidine (Vidaza) and decitabine (Dacogen).
In the U.S., myelodysplastic syndromes (MDS) occur at a rate of 4.8 cases for every 100,000 people, positively impacting the myelodysplastic syndrome treatment adoption trends.
In addition to this, the adoption of myelodysplastic syndrome treatment is on the surge as the number of new cases diagnosed each year seems to be increasing as the average age of the population increases. (Source: American Cancer Society).
Furthermore, diagnosis techniques such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS, leading to the demand for myelodysplastic syndrome treatment.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The myelodysplastic syndrome treatment market size is expected to expand to a significant extent in the coming few years due to increasing mutation in treatments, which cause myelodysplastic syndrome.
Moreover, growing number of patient pool of age 50 and above, and rising government support for cancer treatment augurs well for the myelodysplastic syndrome treatment market future trends.
However, unawareness about such treatments is one of the major factors mitigating the demand for myelodysplastic syndrome treatment.
The complexity and clonal heterogeneity of MDS also pose a challenge to the myelodysplastic syndrome treatment growth as it is frequently unknown, which mutations are early initiating events and are later events that only affect a subclone.
Despite these concerns, researchers are currently testing a number of strategies to try to enhance existing MDS therapeutics, in turn, create numerous myelodysplastic syndrome treatment market opportunities.
One of such myelodysplastic syndrome treatment market trends is the combination therapies that have either additive or synergistic effects in vitro.
Higher response rates than those seen with either drug alone may be possible when azacitidine is combined with lenalidomide or vorinostat (a deacetylase inhibitor currently FDA approved for treating cutaneous T-cell lymphoma).
The myelodysplastic syndrome treatment market outlook is to be swayed by a cooperative group trial in the United States and Canada that are currently investigating whether these combinations will improve patient outcomes in comparison to azacitidine monotherapy.
Due to the rising healthcare costs, and rising end-user demand for myelodysplastic syndrome treatment, North America is anticipated to control a myelodysplastic syndrome treatment market share of 34.6% in 2022.
And as the growth is further fostered by the focus of major players and non-profit organisations present on launching new initiatives and public awareness campaigns to inform people about gout disease and support medical professionals.
A growing awareness of MDS among Americans is expected to cause the U.S. to expand the myelodysplastic syndrome treatment market size over the forecast period.
Principal Consultant
Europe is predicted to experience significant growth and hold a market share of 31.1% in 2022 due to an increase in governmental initiatives for disease diagnosis and treatment.
As an illustration, the European LeukemiaNet WP8 promoted a programme with the goal of creating and regularly updating evidence- and consensus-based guidelines to provide clinical practise recommendations for standardised diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with primary MDS.
A significant factor that is anticipated to propel the myelodysplastic syndrome treatment market share of Europe is the increasing efforts made by pharmaceutical companies to introduce highly effective therapies for MDS.
The oral medication tamibarotene from Syros Pharmaceuticals has been given orphan drug designation (ODD) by the US Food and Drug Administration (FDA) to treat myelodysplastic syndrome (MDS).
A selective retinoic acid receptor alpha (RAR) agonist is tamibarotene.
In the Phase III SELECT-MDS-1 clinical trial, oral therapy is currently being evaluated in addition to azacitidine to treat RARA-positive patients with recently discovered higher-risk MDS (HR-MDS).
The effectiveness and safety of the combination therapy are being evaluated in this ongoing trial.
The pivotal trial's results are expected by the company in the fourth quarter of 2019 or the first quarter of 2024.
In 2024, Syros also intends to submit a potential new drug application.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The myelodysplastic syndrome treatment market is consolidated with a presence of few strong players from around the globe.
Some of the players identified in global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy's Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., Pfizer, Inc. etc.
Emerging trends in myelodysplastic syndrome treatment market are brought about as a result of the major players' adoption of several growth strategies, including product launches, acquisitions, and collaborations.
Some of the recent developments in the myelodysplastic syndrome treatment market are as follows:
Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).
| Report Attribute | Details |
|---|---|
|
Growth Rate |
CAGR of 5.9% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2014-2020 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
The global myelodysplastic syndrome treatment market is set to advance at a CAGR of 5.9% from 2022 to 2032.
North America is likely to hold a myelodysplastic syndrome treatment market share of 34.6% in 2022.
The myelodysplastic syndrome treatment market is likely to account for US$ 5,614.1 million by 2032.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Type, 2022-2032
5.3.1. Refractory cytopenia with unilineage dysplasia (RCUD)
5.3.2. Refractory anemia with ringed sideroblasts (RARS)
5.3.3. Refractory cytopenia with multilineage dysplasia (RCMD)
5.3.4. Refractory anemia with excess blasts-1 (RAEB-1)
5.3.5. Refractory anemia with excess blasts-2 (RAEB-2)
5.3.6. Myelodysplastic syndrome, unclassified (MDS-U)
5.3.7. Myelodysplastic syndrome associated with isolated del(5q)
5.4. Y-o-Y Growth Trend Analysis By Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Type, 2022-2032
6. Global Market 2017-2021 and Forecast 2022-2032, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Stem cell transplantation / bone marrow transplantation
6.3.4. Growth Factors
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2017-2021
6.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032
7. Global Market 2017-2021 and Forecast 2022-2032, By Patient Group
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Patient Group, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Patient Group, 2022-2032
7.3.1. Above 50 years
7.3.2. Below 50 years
7.4. Y-o-Y Growth Trend Analysis By Patient Group, 2017-2021
7.5. Absolute $ Opportunity Analysis By Patient Group, 2022-2032
8. Global Market 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Treatment
9.2.4. By Patient Group
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment
9.3.4. By Patient Group
9.4. Key Takeaways
10. Latin America Market 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Treatment
10.2.4. By Patient Group
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment
10.3.4. By Patient Group
10.4. Key Takeaways
11. Europe Market 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Treatment
11.2.4. By Patient Group
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment
11.3.4. By Patient Group
11.4. Key Takeaways
12. Asia Pacific Market 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. Rest of Asia Pacific
12.2.2. By Type
12.2.3. By Treatment
12.2.4. By Patient Group
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment
12.3.4. By Patient Group
12.4. Key Takeaways
13. MEA Market 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Type
13.2.3. By Treatment
13.2.4. By Patient Group
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment
13.3.4. By Patient Group
13.4. Key Takeaways
14. Key Countries Market
14.1. U.K.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Type
14.1.2.2. By Treatment
14.1.2.3. By Patient Group
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Type
14.2.2.2. By Treatment
14.2.2.3. By Patient Group
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Type
14.3.2.2. By Treatment
14.3.2.3. By Patient Group
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Type
14.4.2.2. By Treatment
14.4.2.3. By Patient Group
14.5. Rest of Latin America
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Type
14.5.2.2. By Treatment
14.5.2.3. By Patient Group
14.6. Germany
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Type
14.6.2.2. By Treatment
14.6.2.3. By Patient Group
14.7. U.K.
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Type
14.7.2.2. By Treatment
14.7.2.3. By Patient Group
14.8. France
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Type
14.8.2.2. By Treatment
14.8.2.3. By Patient Group
14.9. Spain
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Type
14.9.2.2. By Treatment
14.9.2.3. By Patient Group
14.10. Italy
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Type
14.10.2.2. By Treatment
14.10.2.3. By Patient Group
14.11. Rest of Europe
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Type
14.11.2.2. By Treatment
14.11.2.3. By Patient Group
14.12. China
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Type
14.12.2.2. By Treatment
14.12.2.3. By Patient Group
14.13. Japan
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Type
14.13.2.2. By Treatment
14.13.2.3. By Patient Group
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Type
14.14.2.2. By Treatment
14.14.2.3. By Patient Group
14.15. Malaysia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Type
14.15.2.2. By Treatment
14.15.2.3. By Patient Group
14.16. Singapore
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Type
14.16.2.2. By Treatment
14.16.2.3. By Patient Group
14.17. Australia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Type
14.17.2.2. By Treatment
14.17.2.3. By Patient Group
14.18. Rest of Asia Pacific
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Type
14.18.2.2. By Treatment
14.18.2.3. By Patient Group
14.19. GCC Countries
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Type
14.19.2.2. By Treatment
14.19.2.3. By Patient Group
14.20. South Africa
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Type
14.20.2.2. By Treatment
14.20.2.3. By Patient Group
14.21. Israel
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Type
14.21.2.2. By Treatment
14.21.2.3. By Patient Group
14.22. Rest of MEA
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Type
14.22.2.2. By Treatment
14.22.2.3. By Patient Group
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Type
15.3.3. By Treatment
15.3.4. By Patient Group
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Celgene Corporation
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Otsuka Holdings Co., Ltd
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Sandoz, Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Dr. Reddy's Laboratories, Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Accord Healthcare Ltd.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Mylan N.V.,
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Pfizer, Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Myelodysplastic Syndrome Treatment Market
